SARS-CoV-2
-
Trial drug can significantly block early stages of COVID-19 in engineered human tissues
An international team led by University of British Columbia researcher Dr. Josef Penninger has found a trial drug that effectively blocks the cellular door SARS-CoV-2 uses to infect its hosts.
-
Pilot clinical trial in China to test UBC researcher’s findings as a targeted therapy for COVID-19
A University of British Columbia researcher is part of an international team working with a biotechnology company on a pilot clinical trial of a potential new treatment for patients with severe coronavirus infections in China.
